INGELHEIM, Germany - Wednesday, July 31st 2013 [ME NewsWire]

(BUSINESS WIRE) For Non-US and Non-UK Media

Boehringer Ingelheim (BI) and Eli Lilly and Company today announced enrollment of the first patient into a cardiovascular and renal outcomes trial for linagliptin (Trajenta®). The CARMELINA1 (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with Type 2 Diabetes mellitus at high vascular risk) trial will investigate the once daily dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, on cardiovascular and renal microvascular outcomes in adults with Type 2 Diabetes at risk of cardiovascular and renal events.

Linagliptin (5 mg, once daily) is a once-daily tablet that is used along with diet and exercise and other drug therapies to improve glycaemic control in adults with Type 2 Diabetes.

"Diabetes is a major risk factor for cardiovascular disease, as well as a leading cause of chronic renal failure,” said Dr. Julio Rose ... Read more »

SAN ANTONIO & GATWICK, England - Wednesday, July 31st 2013 [ME NewsWire]

Strategic Transaction Strengthens KCI Leadership Position in Global Wound Care Market While Adding Diversification

Enhances Access to $3.4 Billion Advanced Wound Care Market, Leveraging KCI’s Well-Established Customer Relationships, Brand and Commercial Scale

Complementary Product Portfolio Will Advance Provision of Best-in-Class Solutions to Healthcare Professionals and Patients

(BUSINESS WIRE)-- Kinetic Concepts, Inc. (KCI) announced today that it has signed a definitive agreement to acquire UK-based Systagenix, an established provider of advanced wound care (AWC) products, for a purchase price of $485 million. The combination of Systagenix and KCI will augment KCI’s global position as a leading wound care company with a diverse product portfolio dedicated to changing the practice of medicine and improving patient lives around the world.

"The acquisition of Systagenix advan ... Read more »

TOKYO & CHANDLER, Ariz. - Wednesday, July 31st 2013 [ME NewsWire]

(BUSINESS WIRE)-- Toshiba Corporation (TOKYO: 6502) and Amkor Technology, Inc. (Nasdaq: AMKR) today announced that the companies have completed Amkor’s acquisition of Toshiba Electronics Malaysia Sdn. Bhd. ("TEM”), Toshiba’s semiconductor packaging operation in Malaysia. The transaction also includes Toshiba’s license to Amkor of related intellectual property rights and a manufacturing services agreement between Toshiba and Amkor.

Under the manufacturing services agreement, Toshiba has agreed to purchase and TEM has agreed to supply packaging and test services for certain discrete semiconductor products and analog LSI products.

Established in 1973, TEM has steadily expanded the scale of its packaging operations, primarily of discrete and analog semiconductors. In recent years, its main product has been power semiconductors.

Toshiba positions power semiconductors as a driver of growth for i ... Read more »

ME NewsWire / Business Wire

NEW YORK - Wednesday, July 31st 2013

JPMorgan Chase & Co. (NYSE: JPM) announced today that one of its energy subsidiaries, J.P. Morgan Ventures Energy Corporation, has agreed to a settlement with the U.S. Federal Energy Regulatory Commission resolving the agency’s investigation of the Firm’s bidding and offering of electricity from certain power plants.

As part of the agreement, J.P. Morgan Ventures Energy agreed to pay, without admitting or denying any violations, disgorgement, penalties and interest totaling $410 million. J.P. Morgan Ventures Energy is pleased to have reached an agreement with FERC to put this matter behind it.

The settlement relates to power offered from plants largely acquired in connection with J.P. Morgan’s acquisition of Bear Stearns in 2008. This settlement resolves claims by the FERC’s Office of Enforcement that these offers violated FERC rules.

JPMorgan Chase & Co. (NYSE: JPM) is a leading ... Read more »